Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$27.75 +0.5%	$20.00	$16.10 ▼ $41.94	$3.50B	0.78	2.31 million shs	3.77 million shs
BVNRY Bavarian Nordic	$12.37 0.0%	$10.14	$6.60 ▼ $14.60	$2.93B	1.36	7,952 shs	2,798 shs
HCM HUTCHMED	$16.45 +3.7%	$16.48	$11.51 ▼ $21.50	$2.87B	0.55	82,877 shs	34,059 shs
PHGUF Pharming Group	$1.16	$1.15	$0.75 ▼ $1.19	$778.44M	0.65	300 shs	N/A

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	+3.91%	+13.52%	+42.74%	+58.28%	-23.32%
BVNRY Bavarian Nordic	-0.76%	+0.36%	+33.24%	+50.18%	-9.07%
HCM HUTCHMED	-0.81%	-2.70%	-4.17%	+18.52%	-16.95%
PHGUF Pharming Group	0.00%	+1.75%	+0.87%	+27.05%	+40.62%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLS Apellis Pharmaceuticals	4.015 of 5 stars	3.3	1.0	0.0	4.4	2.6	2.5	0.6
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	2.8541 of 5 stars	3.5	2.0	0.0	0.0	3.0	0.0	1.9
PHGUF Pharming Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.58	Moderate Buy	$34.12	22.95% Upside
BVNRY Bavarian Nordic	0.00	N/A	N/A	N/A
HCM HUTCHMED	3.00	Buy	$28.00	70.21% Upside
PHGUF Pharming Group	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest PHGUF, HCM, APLS, and BVNRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	HCM HUTCHMED	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/4/2025	APLS Apellis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$35.00 ➝ $37.00
8/1/2025	APLS Apellis Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$17.00 ➝ $19.00
8/1/2025	APLS Apellis Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$39.00 ➝ $40.00
8/1/2025	APLS Apellis Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$52.00 ➝ $50.00
7/29/2025	APLS Apellis Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$41.00 ➝ $46.00
7/22/2025	HCM HUTCHMED	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00 ➝ $28.00
7/18/2025	APLS Apellis Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$47.00 ➝ $50.00
7/16/2025	APLS Apellis Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
7/2/2025	APLS Apellis Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $26.00
6/2/2025	APLS Apellis Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$26.00 ➝ $29.00

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$781.37M	4.49	N/A	N/A	$1.24 per share	22.38
BVNRY Bavarian Nordic	$829.12M	3.53	$1.00 per share	12.31	$6.99 per share	1.77
HCM HUTCHMED	$630.20M	4.55	$0.30 per share	55.70	$7.12 per share	2.31
PHGUF Pharming Group	$297.20M	2.62	$0.01 per share	154.36	$0.33 per share	3.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	-$197.88M	-$1.82	N/A	N/A	N/A	-30.24%	-116.09%	-26.72%	N/A
BVNRY Bavarian Nordic	$143.26M	$0.80	15.46	11.78	N/A	21.11%	11.89%	9.32%	8/28/2025 (Estimated)
HCM HUTCHMED	$37.73M	N/A	0.00	11.27	N/A	N/A	N/A	N/A	N/A
PHGUF Pharming Group	-$11.84M	N/A	0.00	∞	N/A	-2.19%	-3.38%	-1.82%	N/A

Latest PHGUF, HCM, APLS, and BVNRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
7/31/2025	Q2 2025	APLS Apellis Pharmaceuticals	-$0.44	-$0.33	+$0.11	-$0.33	$187.91 million	$171.39 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BVNRY Bavarian Nordic	N/A	N/A	N/A	N/A	N/A
HCM HUTCHMED	N/A	N/A	N/A	N/A	N/A
PHGUF Pharming Group	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	2.90	3.77	3.16
BVNRY Bavarian Nordic	N/A	2.81	1.44
HCM HUTCHMED	0.05	4.65	4.51
PHGUF Pharming Group	0.51	2.76	2.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
BVNRY Bavarian Nordic	N/A
HCM HUTCHMED	8.82%
PHGUF Pharming Group	N/A

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
BVNRY Bavarian Nordic	N/A
HCM HUTCHMED	3.60%
PHGUF Pharming Group	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	126.29 million	118.08 million	Optionable
BVNRY Bavarian Nordic	1,611	236.57 million	N/A	Not Optionable
HCM HUTCHMED	1,811	174.42 million	168.14 million	Not Optionable
PHGUF Pharming Group	382	671.07 million	N/A	Not Optionable

PHGUF, HCM, APLS, and BVNRY Headlines

Recent News About These Companies

Pharming Group (OTCMKTS:PHGUF) Shares Down 0.9% - What's Next?

August 5, 2025 | marketbeat.com

Pharming Group to participate in August investor conference | PHARM Stock News

August 4, 2025 | gurufocus.com

Pharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating

August 1, 2025 | tipranks.com

Pharming Group reports second quarter and first half 2025 financial results and provides ...

July 31, 2025 | gurufocus.com

Pharming Group to report second quarter and first half 2025 financial results and provide business update on July 31

July 17, 2025 | manilatimes.netM

Pharming Group to report second quarter and first half 2025 financial results and provide ...

July 17, 2025 | gurufocus.com

Pharming Group (PHGN.DU)

June 26, 2025 | sg.finance.yahoo.com

Pharming Group N.V.: Pharming Group reports on results of the 2025 Annual General Meeting of Shareholders

June 11, 2025 | finanznachrichten.de

Pharming Group (PHGUF) Q1 2025 Earnings Call Highlights: Revenue Surge and Strategic Growth ...

May 9, 2025 | uk.finance.yahoo.com

Pharming Group announces upcoming presentations at the 2025 Annual Meeting of the Clinical Immunology Society (CIS)

April 25, 2025 | finance.yahoo.com

Pharming announces positive recommendation from NICE for Joenja

April 24, 2025 | finance.yahoo.com

Pharming Group to report first quarter 2025 financial results on May 8

April 24, 2025 | finance.yahoo.com

Pharming Group N.V.: Pharming receives positive recommendation from NICE for Joenja?(leniolisib) as a treatment for APDS

April 23, 2025 | finanznachrichten.de

NICE Recommends Pharming Group's Joenja for Activated Phosphoinositide 3-Kinase Delta Syndrome

April 23, 2025 | precisionmedicineonline.comP

Pharming Group announces the filing of its 2024 Annual Report and Form 20-F

April 3, 2025 | finance.yahoo.com

Pharming Group (PHAR) Receives a Buy from H.C. Wainwright

March 21, 2025 | markets.businessinsider.com

Pharming price target raised to $39 from $30 at Oppenheimer

March 14, 2025 | markets.businessinsider.com

Pharming Group N.V.: Pharming Group reports on results of the 2025 Extraordinary General Meeting of Shareholders

March 4, 2025 | finanznachrichten.de

Pharming Technologies B.V. increases its ownership in Abliva AB (publ) to 92.70 percent

February 20, 2025 | uk.finance.yahoo.com

Pharming Group to participate in February investor conference

February 10, 2025 | finance.yahoo.com

Pharming Group price target raised to EUR 2.15 from EUR 1.60 at RBC Capital

December 20, 2024 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHGUF, HCM, APLS, and BVNRY Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

$27.75 +0.13 (+0.47%)

Closing price 04:00 PM Eastern

Extended Trading

$28.13 +0.38 (+1.37%)

As of 04:35 PM Eastern

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Bavarian Nordic OTCMKTS:BVNRY

$12.37 -0.01 (-0.04%)

As of 03:33 PM Eastern

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

HUTCHMED NASDAQ:HCM

$16.45 +0.58 (+3.65%)

Closing price 04:00 PM Eastern

Extended Trading

$16.37 -0.08 (-0.49%)

As of 04:10 PM Eastern

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

Pharming Group OTCMKTS:PHGUF

$1.16 0.00 (0.00%)

As of 08/14/2025

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time